Skip to content
lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jubilant Therapeutics India Limited
Jubilant Therapeutics Announces Oral Presentation of Phase 1 Clinical Results for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting
November 10, 2026
Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026
September 15, 2026